Perioperative Management of MuSK-Positive Myasthenia Gravis for Cholecystectomy
For a patient with MuSK-positive myasthenia gravis undergoing cholecystectomy, avoid neuromuscular blocking agents entirely and use propofol-remifentanil based anesthesia, with mandatory quantitative neuromuscular monitoring if any paralytic is absolutely required, and plan for intensive postoperative respiratory monitoring given the high risk of bulbar and respiratory complications specific to MuSK-MG. 1
Preoperative Assessment
MuSK-positive MG differs critically from acetylcholine receptor antibody MG—these patients have predominantly bulbar, ocular, and respiratory muscle involvement with higher aspiration risk and treatment refractoriness 1, 2. Your preoperative workup must include:
- Comprehensive pre-anesthetic assessment is mandatory to plan anesthesia, estimate risk, and obtain informed consent 3
- Pulmonary function tests in all patients with clinical signs of reduced respiratory capacity or decreased muscle reserves 3
- ECG and echocardiography if there is any suspicion of cardiac involvement or the patient is on cardiac medications 3
- Blood work: electrolytes, creatine kinase, kidney and liver function tests, acid-base/lactate 3
- Avoid benzodiazepine premedication in patients with muscle weakness 3
Critical pitfall: MuSK-MG patients are generally more refractory to standard treatments than AChR-MG patients 2. Do not assume their disease is well-controlled based on typical MG management.
Anesthetic Technique Selection
Regional anesthesia is preferred to general anesthesia when feasible for the procedure 3. For cholecystectomy, consider:
- Laparoscopic approach under regional techniques if expertise available
- If general anesthesia required, use total intravenous anesthesia (TIVA) with propofol and remifentanil 1
Intraoperative Management: Neuromuscular Blockade
The safest approach is to avoid neuromuscular blocking agents entirely 1. If intubation is required:
- Use remifentanil or alfentanil bolus to facilitate intubation without paralytics 3
- Suxamethonium is absolutely contraindicated in all myopathies due to risk of life-threatening hyperkalemia, rhabdomyolysis, and cardiac arrest 3
If neuromuscular blockade is deemed absolutely necessary:
- Use rocuronium at <50% typical dose (0.3 mg/kg instead of 0.6 mg/kg) 3
- Sugammadex must be immediately available 3
- Mandatory quantitative neuromuscular monitoring with train-of-four ratio >0.9 before extubation 3
- Rocuronium and vecuronium are preferred as they can be fully reversed by sugammadex, which is superior to neostigmine/glycopyrrolate in myopathies 3
Critical warning: Even with reduced doses, prolonged neuromuscular blockade can occur, resulting in postoperative residual paralysis 3. MG patients have unpredictable responses to both depolarizing and non-depolarizing agents 4, 5.
Pain Management
Use multimodal analgesia with short-acting opioids to minimize respiratory depression 3:
- Regional anesthesia techniques optimize postoperative pain control 3
- Peripheral nerve blocks for adjunct pain control 4
- Limit opioid use given bulbar and respiratory muscle weakness in MuSK-MG 1, 4
- Patient-controlled analgesia (PCA) only in PACU or settings with continuous pulse oximetry 3
Postoperative Management
Plan for intensive monitoring and have ICU support pre-arranged 3. MuSK-MG patients have:
- High risk of respiratory failure and myasthenic crisis perioperatively 1, 5
- Bulbar involvement increases aspiration risk 1
- Postoperative myasthenic crisis (respiratory failure requiring prolonged ventilation or re-intubation) remains a significant complication 6
Extubation criteria must be stringent:
- Absolutely no residual curarization 4
- Sufficient spontaneous breathing with adequate tidal volumes
- Strong cough and ability to protect airway given bulbar weakness risk
Do not routinely admit to ICU if patient meets strict extubation criteria and has minimal disease manifestations, but have ICU immediately available 4.
MuSK-Specific Considerations
The case report 1 demonstrates successful management of MuSK-MG cholecystectomy using propofol-remifentanil without muscle relaxants. This approach is particularly appropriate because:
- MuSK-MG has both presynaptic and postsynaptic dysfunction 2
- These patients are more refractory to standard treatments including acetylcholinesterase inhibitors 2, 7
- Bulbar and respiratory symptoms predominate, increasing perioperative risk 1, 2
The most effective therapies for MuSK-MG are corticosteroids, plasmapheresis, and rituximab 2, but routine preoperative IVIg or plasmapheresis is not supported by current evidence for well-controlled patients 6.